Maxim Chernin

Maxim Chernin



+7 495 545-39-12

Send message

Maxim has joined to the "Team Drive" in October 2017.

Before that, he headed the Client’s Welfare Department of Sberbank as a Managing director. He was a board member of subsidiaries and played a key part in developing insurance, pension and investment activity of this biggest Russian bank. In 2010 as a CEO Maxim organized from scratch “Sberbank life insurance” project. Today it is recognized market leader in its field. Maxim’s professional record includes 10 years experience in insurer company Allianz (former ROSNO). He started as a specialist of marketing research department and in few years he became a member of the Management Board with a wide range of responsibilities. Companies and departments had been growing strongly under his guidance. His management was cost-effective, profitable for shareholders and provided high-quality services for the clients.

Now Maxim is a member of the Government Expert Council of the Russian Federation and of the Public Council under the Ministry of Health of the Russian Federation.

Since 2010 Maxim leads the committee of life insurance in the All-Russian Insurance Association (ARIA). He is also a member of the Board of the All-Russian Insurance Association and of the Association of Life Insurers. In addition, Maxim is a Board member of PJSC Rosgosstrakh insurance company.

In 2017, Maxim was awarded by the National Financial Award “Reputation” in the nomination “For Personal Merits in the Development of Insurance in Russia”. In 2016 he was included into the “Top 250 of the Russian principals” rating according to the estimation of “Kommersant” magazine. In 2014, Maxim was awarded the ARIA honorary medal "For Merits in the Development of Insurance in Russia". In 2011, the “Finance” magazine included Maxim in the annual list of the most successful young businessperson in Russia.

Maxim graduated with honours from the National Research University “Higher School of Economics” majoring in “Strategic Management”.

Media Center

  • 14 December 2017

    Will Pharma Meet the Drug Tracking Deadline?

    As FDA and industry near the halfway mark in the 10-year process for establishing a national electronic drug tracking system by 2023, there’s considerable concern among pharma companies, wholesaler/distributors, and pharmacists about meeting the deadline. The process for establishing the rules and infrastructure for the track-and-trace system envisioned in the Drug Supply Chain Security Act (DSCSA), part of the Drug Quality and Security Act of 2013 (DQSA), is proving to be complex and challenging for all parties.

  • 14 December 2017

    Russia’s pharma imports resume growth for the first time since 2014

    Drug imports by Russia for the period of January-September of 2017 grew for the first time since 2014 and amounted to 108.700 tonnes, which is 6.5% more than in the same period a year ago.

  • 13 December 2017

    Drug Name Development: Regulatory Changes You Need to Know

    Small changes in regulatory guidance can translate to big risks if you’re not adjusting your strategy and timelines proactively. A delay as short as six months in a pharmaceutical product launch can result in an average loss of $100 million.

  • 13 December 2017

    Survey Measures Biopharma Career Highs and Lows

    Complex biologic drugs, including personalized medicines, demand more sophisticated formulation and manufacturing methods, as well as talented, experienced pharmaceutical scientists and engineers to deliver therapies to patients. Advanced technology for manufacturing is expected to increase the required skill sets of biopharma workers.

Read more